|
ES517193A0
(es)
|
1981-11-10 |
1983-12-01 |
Wellcome Found |
Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina.
|
|
US4847256A
(en)
|
1986-10-16 |
1989-07-11 |
American Cyanamid Company |
4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
|
|
AU650953B2
(en)
|
1991-03-21 |
1994-07-07 |
Novartis Ag |
Inhaler
|
|
US5728536A
(en)
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
|
US6136595A
(en)
|
1993-07-29 |
2000-10-24 |
St. Jude Children's Research Hospital |
Jak kinases and regulations of cytokine signal transduction
|
|
US5543523A
(en)
|
1994-11-15 |
1996-08-06 |
Regents Of The University Of Minnesota |
Method and intermediates for the synthesis of korupensamines
|
|
US5705625A
(en)
|
1994-12-15 |
1998-01-06 |
The Johns Hopkins University School Of Medicine |
Nucleic Acid Encoding novel protein tyrosine kinase
|
|
US7070972B1
(en)
|
1995-01-13 |
2006-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Janus family kinases and identification of immune modulators
|
|
US6034057A
(en)
|
1995-07-06 |
2000-03-07 |
Zeneca Limited |
Peptide inhibitors of fibronectine
|
|
US6248713B1
(en)
|
1995-07-11 |
2001-06-19 |
Biogen, Inc. |
Cell adhesion inhibitors
|
|
US7091020B1
(en)
|
1995-12-05 |
2006-08-15 |
Incyte Corporation |
Human Jak2 kinase
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
US6235741B1
(en)
|
1997-05-30 |
2001-05-22 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
|
FR2791562B1
(fr)
|
1999-03-29 |
2004-03-05 |
Oreal |
Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture
|
|
YU25500A
(sh)
|
1999-05-11 |
2003-08-29 |
Pfizer Products Inc. |
Postupak za sintezu analoga nukleozida
|
|
NZ516260A
(en)
|
1999-07-02 |
2004-08-27 |
Eisai Co Ltd |
Fused imidazole compounds and remedies for diabetes mellitus
|
|
DE60037345T2
(de)
|
1999-12-10 |
2008-11-13 |
Pfizer Products Inc., Groton |
Pyrrolo(2,3-d)pyrimidin-Verbindungen
|
|
GB0028383D0
(en)
|
2000-11-21 |
2001-01-03 |
Novartis Ag |
Organic compounds
|
|
EP1241176A1
(fr)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Dérivés de purine pour le traitement de l'ischémie
|
|
EP1458682B1
(fr)
|
2001-12-20 |
2006-08-30 |
Bayer HealthCare AG |
Derives de 1,4-dihydro-1,4-diphenylpyridine
|
|
JP4500055B2
(ja)
|
2002-04-23 |
2010-07-14 |
塩野義製薬株式会社 |
ピラゾロ［１，５−ａ］ピリミジン誘導体およびそれを含有するＮＡＤ（Ｐ）Ｈオキシダーゼ阻害剤
|
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
|
US7161003B1
(en)
|
2002-09-04 |
2007-01-09 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
US7129239B2
(en)
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
|
AU2003270701B2
(en)
|
2002-10-31 |
2009-11-12 |
Amgen Inc. |
Antiinflammation agents
|
|
US7550470B2
(en)
|
2002-12-11 |
2009-06-23 |
Merck & Co. Inc. |
Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
|
|
JP2006522744A
(ja)
|
2003-04-11 |
2006-10-05 |
ノボ ノルディスク アクティーゼルスカブ |
グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
|
|
JP2006522750A
(ja)
|
2003-04-11 |
2006-10-05 |
ノボ ノルディスク アクティーゼルスカブ |
代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
|
|
US20070270408A1
(en)
|
2003-04-11 |
2007-11-22 |
Novo Nordisk A/S |
Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
|
|
WO2004089471A2
(fr)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Utilisation pharmaceutique de pyrazolo[1,5-a]pyrimidines substituees
|
|
WO2005004810A2
(fr)
|
2003-07-02 |
2005-01-20 |
Merck & Co., Inc. |
Derives arylsulfonamide
|
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
|
SE0302487D0
(sv)
|
2003-09-18 |
2003-09-18 |
Astrazeneca Ab |
Novel compounds
|
|
GB0329214D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Novel compounds
|
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
|
WO2005110477A2
(fr)
|
2004-04-09 |
2005-11-24 |
University Of South Florida |
Polytherapies pour le cancer et des angiopathies proliferantes
|
|
US7517888B2
(en)
|
2004-04-28 |
2009-04-14 |
Cv Therapeutics, Inc. |
A1 adenosine receptor antagonists
|
|
US20050288502A1
(en)
|
2004-06-25 |
2005-12-29 |
Andersen Denise L |
Substituted heterocyclic compounds and methods of use
|
|
CN101094853B
(zh)
|
2004-11-04 |
2011-07-13 |
沃泰克斯药物股份有限公司 |
可用作蛋白激酶抑制剂的吡唑并[1,5-a]嘧啶
|
|
GB0502258D0
(en)
|
2005-02-03 |
2005-03-09 |
Argenta Discovery Ltd |
Compounds and their use
|
|
US20100216798A1
(en)
|
2005-07-29 |
2010-08-26 |
Astellas Pharma Inc |
Fused heterocycles as lck inhibitors
|
|
WO2007039797A1
(fr)
|
2005-10-03 |
2007-04-12 |
Pfizer Products Inc. |
Utilisation d'antagonistes du recepteur cannabinoide de type 1 pour traiter les inflammations et l'arthrite
|
|
KR20080063806A
(ko)
*
|
2005-10-06 |
2008-07-07 |
쉐링 코포레이션 |
단백질 키나제 억제제로서의 피라졸로피리미딘
|
|
CA2624500A1
(fr)
|
2005-10-06 |
2007-04-19 |
Schering Corporation |
Pyrazolopyrimidines en tant qu'inhibiteurs de la proteine kinase
|
|
US8101625B2
(en)
|
2005-10-21 |
2012-01-24 |
Exelixis, Inc. |
Pyrimidinones as Casein Kinase II (CK2) modulators
|
|
KR20080074161A
(ko)
|
2005-12-08 |
2008-08-12 |
노파르티스 아게 |
ＥＰＨＢ 및 ＶＥＧＦＲ２ 키나아제 억제제로서의피라졸로[１,５-ａ]피리딘-３-카르복실산
|
|
US8541406B2
(en)
|
2006-02-07 |
2013-09-24 |
Nv Remynd |
Thiadiazole derivatives for the treatment of neurodegenerative diseases
|
|
TW200800997A
(en)
|
2006-03-22 |
2008-01-01 |
Astrazeneca Ab |
Chemical compounds
|
|
AR061793A1
(es)
|
2006-07-05 |
2008-09-24 |
Mitsubishi Tanabe Pharma Corp |
Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
|
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
BRPI0718266A2
(pt)
|
2006-10-30 |
2014-01-07 |
Novartis Ag |
Compostos heterocíclicos como agentes anti-inflamatórios.
|
|
AU2007321924A1
(en)
|
2006-11-20 |
2008-05-29 |
Alantos Pharmaceuticals Holding, Inc. |
Heterobicyclic metalloprotease inhibitors
|
|
WO2009017954A1
(fr)
|
2007-08-01 |
2009-02-05 |
Phenomix Corporation |
Inhibiteurs de kinase jak2
|
|
CN104151293A
(zh)
|
2007-10-12 |
2014-11-19 |
阿斯利康公司 |
蛋白激酶抑制剂
|
|
EP3912973A3
(fr)
|
2007-11-28 |
2022-02-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de myristate de bcr-abl à petite molécule et procédés d'utilisation
|
|
CA2709784A1
(fr)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Procede permettant de modifier la duree de vie d'organismes eucaryotes
|
|
PE20110545A1
(es)
|
2008-06-20 |
2011-08-18 |
Genentech Inc |
Compuestos de triazolopiridina como inhibidores de jak
|
|
WO2010019762A1
(fr)
|
2008-08-13 |
2010-02-18 |
Jenrin Discovery |
Composés de purine en tant que bloqueurs de récepteur aux cannabinoïdes
|
|
RU2539568C2
(ru)
|
2008-10-31 |
2015-01-20 |
Дженентек, Инк. |
Пиразолопиримидиновые соединения-ингибиторы jak и способы
|
|
WO2010063487A1
(fr)
|
2008-12-05 |
2010-06-10 |
Merz Pharma Gmbh & Co. Kgaa |
Pyrazolopyrimidines, procédé pour leur préparation et leur utilisation comme médicament
|
|
EP2393804B1
(fr)
|
2009-02-06 |
2014-04-16 |
Janssen Pharmaceuticals, Inc. |
Nouveaux composés hétérocycliques bicycliques substitués en tant que modulateurs de la secrétase gamma
|
|
TWI461425B
(zh)
|
2009-02-19 |
2014-11-21 |
Janssen Pharmaceuticals Inc |
作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
|
|
UA110324C2
(en)
|
2009-07-02 |
2015-12-25 |
Genentech Inc |
Jak inhibitory compounds based on pyrazolo pyrimidine
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
CN102666545B
(zh)
|
2009-10-20 |
2016-04-06 |
塞尔卓姆有限公司 |
作为jak抑制剂的杂环吡唑并嘧啶类似物
|
|
KR20130001272A
(ko)
|
2010-03-17 |
2013-01-03 |
에프. 호프만-라 로슈 아게 |
이미다조피리딘 및 푸린 화합물, 조성물 및 사용 방법
|
|
KR20130094693A
(ko)
|
2010-04-30 |
2013-08-26 |
셀좀 리미티드 |
Ｊａｋ 저해제로서의 피라졸 화합물
|
|
WO2012007375A1
(fr)
|
2010-07-13 |
2012-01-19 |
F. Hoffmann-La Roche Ag |
Dérivés pyrazolo [1,5a] pyrimidine et thiéno [3,2b] pyrimidine en tant que modulateurs de irak4
|
|
WO2012075393A2
(fr)
|
2010-12-02 |
2012-06-07 |
President And Fellows Of Harvard College |
Activateurs de la dégradation protéasomique et leurs utilisations
|
|
EP2688872A4
(fr)
*
|
2011-03-22 |
2014-08-27 |
Merck Sharp & Dohme |
Inhibiteurs de kinases associées aux récepteurs d'interleukine à base d'amidopyrazole
|
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
|
EP2892899B1
(fr)
|
2012-09-06 |
2018-03-21 |
Bristol-Myers Squibb Company |
Inhibiteurs de jak3 de type imidazopyridazine et leur utilisation pour le traitement de maladies inflammatoires et auto-immunes
|
|
EP2917181B1
(fr)
|
2012-11-09 |
2019-09-25 |
Jacobus Pharmaceutical Company, Inc. |
Dérivés hétéroaryles et leurs utilisations
|
|
WO2015006181A1
(fr)
|
2013-07-11 |
2015-01-15 |
Merck Sharp & Dohme Corp. |
Inhibiteurs amidopyrazole substitués de kinases associées aux récepteurs de l'interleukine (irak -4)
|
|
WO2015068856A1
(fr)
|
2013-11-08 |
2015-05-14 |
Takeda Pharmaceutical Company Limited |
Pyrazole pour le traitement de troubles auto-immuns
|
|
WO2015073267A1
(fr)
|
2013-11-15 |
2015-05-21 |
Calitor Sciences, Llc |
Composés hétéroaryle substitués et méthodes d'utilisation
|
|
PE20170663A1
(es)
*
|
2014-05-23 |
2017-05-22 |
Hoffmann La Roche |
Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
|
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
WO2015179840A1
(fr)
|
2014-05-23 |
2015-11-26 |
Phibro Animal Health Corporation |
Combinaison, composition et méthode d'administration de la combinaison ou de la composition à des animaux
|
|
KR102662215B1
(ko)
|
2014-11-06 |
2024-05-02 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
|
|
EP3268367B8
(fr)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamides utilisés comme inhibiteurs de l'activité de l'irak4
|
|
US10040798B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of IRAK4 activity
|
|
EP3268006B1
(fr)
|
2015-03-12 |
2020-01-08 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de pyrrolotriazine de l'activité d'irak4
|
|
EP3267996B1
(fr)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activité d'irak4 à base de pyrazolopyrimidine
|
|
TW201720828A
(zh)
|
2015-11-23 |
2017-06-16 |
赫孚孟拉羅股份公司 |
治療性化合物及組合物以及其使用方法
|
|
CN108473501B
(zh)
|
2016-02-18 |
2021-07-16 |
豪夫迈·罗氏有限公司 |
治疗化合物、其组合物及使用方法
|
|
CN110114343B
(zh)
|
2016-12-29 |
2022-09-06 |
豪夫迈·罗氏有限公司 |
吡唑并嘧啶化合物及其使用方法
|
|
CN110494434B
(zh)
|
2017-03-14 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
吡唑并氯苯基化合物、其组合物及其使用方法
|
|
CA3061236A1
(fr)
*
|
2017-05-22 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Composes therapeutiques, compositions et procedes d'utilisation associes
|
|
JP7228318B6
(ja)
|
2017-05-22 |
2023-03-10 |
エフ． ホフマン－ラ ロシュ アーゲー |
処置用化合物及び組成物、並びにその使用方法
|